共 50 条
- [1] Risedronate is well-tolerated in women with postmenopausal osteoporosis.[J]. JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 : S538 - S538McClung, MEastell, RWatts, NFogelman, IHooper, MErnst, TBettica, PReginster, JY
- [2] Risedronate is well-tolerated in alendronate-intolerant postmenopausal women.[J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 : S429 - S429Adachi, JAdami, SMiller, POlszynski, WPKendler, DSilverman, SLicata, ALi, ZStevens, KLong, PH
- [3] Risedronate is well-tolerated in postmenopausal women who are GI-intolerant to alendronate[J]. BONE, 2001, 28 (05) : S228 - S228Adami, SAdachi, JDMiller, PDHorlait, S
- [4] Risedronate increases bone mineral density and is well-tolerated in postmenopausal women with low bone mineral density.[J]. JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 : S136 - S136Ribot, CSmith, RFogelman, IBettica, PPack, SEthgen, DReginster, JY
- [5] Risedronate is well-tolerated in patients with osteoporosis including those over 80 years of age[J]. OSTEOPOROSIS INTERNATIONAL, 2000, 11 : S173 - S174Bolognese, MMcIntyre, DFogelman, IOlszynski, WBeck-Nielsen, HMulder, HBarton, IErnst, TChines, A
- [6] Intravenous ibandronate is an effective and well-tolerated treatment for osteoporosis [J]. Nature Clinical Practice Rheumatology, 2008, 4 (7): : 335 - 335
- [8] Risedronate for prevention and treatment of osteoporosis in postmenopausal women[J]. EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (03) : 465 - 477Recker, RRBarger-Lux, J
- [10] Fulvestrant: a new, effective and well-tolerated secondline treatment option for postmenopausal women with advanced breast cancer[J]. BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S237 - S237Dodwell, DVergote, I